Global Myiasis Treatment Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Myiasis Treatment Market Size

• The global myiasis treatment market size was valued at USD 499.72 million in 2024 and is expected to reach USD 738.31 million by 2032, at a CAGR of 5.00% during the forecast period
• The market growth is largely fueled by the increasing prevalence of myiasis cases, rising awareness about parasitic infestations, and advancements in treatment options, leading to improved patient outcomes in both humans and animals
• Furthermore, growing demand for effective, safe, and accessible treatment solutions is establishing myiasis therapeutics as the preferred choice for managing infestations. These converging factors are accelerating the adoption of myiasis treatment solutions, thereby significantly boosting the industry's growth

Myiasis Treatment Market Analysis

• Myiasis treatment, involving pharmaceutical and surgical interventions for parasitic fly larvae infestations, is gaining significance due to rising incidences in humans, increasing temperatures, and expanding fly populations across regions
• The escalating demand for myiasis treatment is primarily fueled by increasing prevalence of myiasis, awareness of treatment options, and government initiatives to improve healthcare infrastructure, particularly in tropical and subtropical regions
• North America dominated the myiasis treatment market with the largest revenue share of 38.4% in 2024, characterized by high healthcare spending, advanced medical facilities, and strong presence of key pharmaceutical companies focusing on parasitic disease treatments
• Asia-Pacific is expected to be the fastest growing region in the myiasis treatment market during the forecast period due to rising healthcare investments, government initiatives to establish pharmaceutical facilities, and increasing accessibility of treatment in urban and rural areas
• Ivermectin segment dominated the myiasis treatment market with a market share of 42.6% in 2024, owing to its high efficacy and widespread clinical adoption for treating various forms of myiasis

Report Scope and Myiasis Treatment Market Segmentation 

Myiasis Treatment Market Trends

Rising Incidence Due to Climate Change and Urbanization

• A significant and accelerating trend in the myiasis treatment market is the increasing incidence of myiasis cases, driven by rising temperatures and the invasion of new fly species
  • For instance, in Sub-Saharan Africa, the prevalence of human myiasis is influenced by factors such as poor hygiene, low socioeconomic status, and climatic conditions that favor fly proliferation
• This trend is leading to a higher demand for effective myiasis treatment options, including pharmaceuticals such as ivermectin and lidocaine, as well as surgical interventions such as debridement
• The increasing burden of myiasis is prompting healthcare providers to focus on early detection and timely treatment to prevent complications
• This trend is reshaping the landscape of myiasis treatment, with a growing emphasis on preventive measures and public health initiatives to combat the disease
  • For instance, awareness campaigns and community health programs are being implemented in endemic regions to reduce exposure and educate populations about early treatment
• Innovations in minimally invasive treatment techniques are emerging, improving patient comfort and reducing recovery times, further influencing market dynamics

Myiasis Treatment Market Dynamics

Driver

Rising Incidence of Myiasis and Increasing Healthcare Expenditure

• The growing prevalence of myiasis in humans is a significant driver for the myiasis treatment market. For instance, in regions such as Sub-Saharan Africa, the incidence of myiasis is increasing due to factors such as poor hygiene and climatic conditions favorable to fly proliferation
• In addition, rising healthcare expenditure is enabling better access to treatment options and improving healthcare infrastructure in affected regions
• Furthermore, increasing research activities are leading to the development of more effective treatment modalities for myiasis
• These factors combined are expected to drive the growth of the myiasis treatment market during the forecast period
  • For instance, government funding for neglected tropical diseases is enabling faster development and deployment of myiasis treatments in endemic regions
• The expansion of healthcare facilities in rural areas is providing improved access to treatment, directly supporting market growth

Restraint/Challenge

Adverse Drug Effects and Regulatory Challenge

• Concerns regarding adverse effects related to drugs used in myiasis treatment pose a significant challenge to market growth
  • For instance, post-debridement complications can arise, leading to prolonged recovery times and increased healthcare costs
• In addition, strict regulatory frameworks in various regions can delay the approval and availability of new treatment options
• These challenges necessitate ongoing research and development efforts to improve treatment efficacy and safety profiles
• Addressing these issues is crucial for the sustained growth and advancement of the myiasis treatment market. For instance, limited awareness among healthcare providers in remote areas can lead to misdiagnosis or delayed treatment, hindering market adoption
• High treatment costs in certain regions may restrict patient access, particularly in low-income countries, further challenging market expansion

Myiasis Treatment Market Scope

The market is segmented on the basis of treatment, route of administration, end-users, and distribution channel.

• By Treatment

On the basis of treatment, the myiasis treatment market is segmented into Xylocaine, Ivermectin, Lidocaine, and Debridement. The Ivermectin segment dominated the market with the largest market revenue share of 42.6% in 2024, owing to its high efficacy against various forms of myiasis and widespread clinical adoption. Healthcare providers prefer Ivermectin for its oral and topical formulations that allow flexible treatment approaches. The drug is cost-effective and widely available, making it the first-line therapy in many endemic regions. Its ease of administration, minimal side effects, and proven effectiveness in controlling parasitic infestations further support its dominance. In addition, ongoing research and government programs promoting antiparasitic treatments contribute to the continued market preference for Ivermectin.

The Debridement segment is anticipated to witness the fastest growth rate from 2025 to 2032, fueled by increasing adoption of minimally invasive surgical techniques and rising awareness of effective wound management. Debridement allows direct removal of larvae, offering immediate relief in severe cases and reducing secondary infections. Hospitals and clinics are increasingly adopting advanced debridement technologies, improving patient outcomes. Rising investments in healthcare infrastructure and training of medical personnel further drive the growth of this segment. Moreover, integration with complementary pharmaceutical treatments enhances its clinical effectiveness and market uptake.

• By Route of Administration

On the basis of route of administration, the myiasis treatment market is segmented into oral, topical, and others. The Oral segment dominated the market with the largest share in 2024, driven by the convenience and systemic efficacy of oral medications such as Ivermectin. Oral administration allows treatment of multiple affected sites and reduces the need for frequent hospital visits. It is preferred in regions with limited healthcare infrastructure due to ease of distribution and self-administration under medical guidance. Patient adherence is higher with oral formulations, supporting widespread adoption. The availability of generic oral antiparasitic drugs further enhances affordability and access. For instance, community health programs often distribute oral treatments to control outbreaks effectively.

The Topical segment is expected to witness the fastest growth from 2025 to 2032, fueled by rising preference for localized treatment and minimal systemic exposure. Topical agents such as Xylocaine and Lidocaine provide immediate relief from pain and inflammation. This route is particularly popular in outpatient care and home-based treatments. Increasing awareness about wound care and topical therapy effectiveness drives adoption. Innovations in gel, cream, and spray formulations enhance patient compliance and therapeutic outcomes. In addition, integration with debridement procedures for comprehensive care supports the growth of topical administration.

• By End-Users

On the basis of end-users, the myiasis treatment market is segmented into clinics, hospitals, and others. Hospitals dominated the market with a market share of 55% in 2024, driven by higher patient inflow, better diagnostic facilities, and availability of specialized treatment options. Hospitals provide comprehensive care including oral, topical, and surgical treatments. Availability of trained medical staff and advanced equipment ensures accurate diagnosis and timely intervention. Hospitals also lead in the adoption of new treatment protocols and preventive care programs. For instance, tertiary care centers in endemic regions actively implement treatment campaigns for severe myiasis cases. Government and private hospital initiatives further strengthen the market dominance of this segment.

The Clinics segment is anticipated to witness the fastest growth from 2025 to 2032, fueled by the rising number of outpatient and community clinics in rural and semi-urban regions. Clinics offer convenient and cost-effective treatment options for mild to moderate myiasis cases. Increasing awareness and accessibility of clinic-based care support early intervention and reduce complications. Clinics also promote telemedicine and follow-up care, increasing patient reach. For instance, local clinics often combine pharmacological treatment with minor debridement procedures for effective management. Rising healthcare investment and training programs for clinic staff contribute to segment growth.

• By Distribution Channel

On the basis of distribution channel, the myiasis treatment market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. Hospital Pharmacy dominated the market with the largest share in 2024, driven by the direct supply of prescription medications and surgical products within healthcare facilities. Hospital pharmacies ensure availability of critical drugs such as Ivermectin and Lidocaine for immediate treatment. Integration with hospital inventory and patient management systems enhances efficiency. Hospitals often provide counseling and follow-up support through their pharmacies, improving treatment adherence. For instance, in endemic regions, hospital pharmacies serve as the primary source of myiasis medications. Government-supported hospital pharmacies further reinforce market dominance.

The Online Pharmacy segment is expected to witness the fastest growth from 2025 to 2032, fueled by increasing digital adoption, e-pharmacy platforms, and rising consumer preference for home delivery of medicines. Online channels enhance accessibility for patients in remote or underserved regions. Convenience, competitive pricing, and discreet ordering drive adoption. For instance, telemedicine platforms integrate online pharmacy services to provide comprehensive treatment solutions. Growth in internet penetration and mobile connectivity further accelerates segment expansion. Moreover, partnerships between online pharmacies and local clinics improve drug distribution and patient compliance.

Myiasis Treatment Market Regional Analysis

• North America dominated the myiasis treatment market with the largest revenue share of 38.4% in 2024, characterized by high healthcare spending, advanced medical facilities, and strong presence of key pharmaceutical companies focusing on parasitic disease treatments
• Healthcare providers and patients in the region prioritize effective, timely treatment options, and the presence of well-established pharmaceutical companies ensures the availability of proven therapies such as Ivermectin and Lidocaine
• This widespread adoption is further supported by strong government healthcare programs, advanced diagnostic facilities, and ongoing research initiatives, establishing myiasis treatment as a critical component of infectious disease management in both hospitals and clinics

U.S. Myiasis Treatment Market Insight

The U.S. myiasis treatment market captured the largest revenue share of 75% in 2024 within North America, fueled by increasing awareness of parasitic infections and high healthcare spending. Patients and healthcare providers prioritize timely and effective treatment options, including Ivermectin, Lidocaine, and debridement procedures. The growing focus on preventive healthcare, combined with advanced diagnostic facilities and telemedicine services, further propels market adoption. Moreover, research initiatives and government programs targeting neglected tropical diseases are significantly contributing to the market's expansion.

Europe Myiasis Treatment Market Insight

The Europe myiasis treatment market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by rising awareness of parasitic diseases and well-established healthcare infrastructure. Increasing urbanization, coupled with access to advanced medical treatments, is fostering the adoption of myiasis therapies. European patients are also drawn to effective and rapid treatment options for infestations. The region is witnessing growth across hospitals, clinics, and outpatient centers, with myiasis treatments being incorporated into both routine care and specialized infectious disease programs.

U.K. Myiasis Treatment Market Insight

The U.K. myiasis treatment market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing cases in travelers and localized infestations in rural areas. Concerns regarding hygiene and preventive healthcare are encouraging both hospitals and clinics to adopt standard treatment protocols. In addition, the U.K.’s robust healthcare system and rising research in antiparasitic therapies are expected to continue stimulating market growth. Public health campaigns and the availability of over-the-counter treatments are also supporting market expansion.

Germany Myiasis Treatment Market Insight

The Germany myiasis treatment market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing awareness of parasitic infections and a strong emphasis on healthcare quality and patient safety. Germany’s advanced medical infrastructure and well-trained healthcare professionals promote the adoption of both pharmaceutical and surgical treatment options. Hospitals and specialized clinics are increasingly integrating Ivermectin and debridement treatments into patient care. Preventive healthcare programs and research collaborations further support the market, aligning with consumer expectations for safe and effective therapies.

Asia-Pacific Myiasis Treatment Market Insight

The Asia-Pacific myiasis treatment market is poised to grow at the fastest CAGR of 22% during the forecast period of 2025 to 2032, driven by rising prevalence of myiasis in tropical and subtropical countries such as India, China, and Indonesia. Increasing urbanization, improving healthcare infrastructure, and growing government initiatives for infectious disease management are driving market adoption. The affordability and accessibility of treatments such as Ivermectin and Lidocaine are expanding to a wider patient base. Furthermore, telemedicine services and awareness campaigns in rural areas are enhancing early diagnosis and treatment, boosting overall market growth.

Japan Myiasis Treatment Market Insight

The Japan myiasis treatment market is gaining momentum due to increasing awareness of parasitic infections and a focus on preventive healthcare. Japanese hospitals and clinics emphasize early diagnosis and timely treatment using Ivermectin and topical therapies. The integration of telehealth services and advanced medical technologies is fueling growth. Moreover, Japan’s aging population is such asly to spur demand for easier-to-administer, effective treatments in both residential and hospital settings, ensuring improved patient outcomes.

India Myiasis Treatment Market Insight

The India myiasis treatment market accounted for the largest revenue share in Asia-Pacific in 2024, attributed to high prevalence of parasitic infestations, rapid urbanization, and rising healthcare awareness. India remains one of the largest markets for antiparasitic treatments, with Ivermectin, Lidocaine, and debridement widely used across hospitals and clinics. Government initiatives for public health and the promotion of telemedicine services are key factors propelling the market. The availability of affordable treatment options and strong domestic pharmaceutical manufacturers further support market growth

Myiasis Treatment Market Share

The Myiasis Treatment industry is primarily led by well-established companies, including:

• Monarch Labs (U.S.)
• BioMonde (U.K.)
• Smith & Nephew (U.K.)
• B. Braun SE (Germany)
• Mölnlycke Health Care AB (Sweden)
• Coloplast (Denmark)
• Lohmann & Rauscher GmbH & Co. KG (Germany)
• Arobella Medical, LLC (U.S.)
• Zoetis Services LLC. (U.S.)
• Pfizer Inc. (U.S.)
• Aspen Holdings (South Africa)
• Dentsply Sirona, (U.S.)
• Actiza Pharmaceutical Private Limited (India)
• Dr. Reddy’s Laboratories, Inc. (India)
• HISUN USA, Inc. (U.S.)
• LIVEALTH (U.S.)
• Hovione (Portugal)
• medi USA (U.S.)
• Zimmer Biomet (U.S.)

What are the Recent Developments in Global Myiasis Treatment Market?

• In September 2025, Zoetis announced that the U.S. FDA granted conditional approval for Dectomax®-CA1 Injectable, the first and only parasite control product with conditional approval to help control the New World screwworm (Cochliomyia hominivorax) in cattle. This approval marks a significant advancement in the prevention and treatment of myiasis in livestock
• In August 2025, The Texas Legislature passed a bill allowing the over-the-counter sale of ivermectin, a medication used to treat parasitic infections, including myiasis. This legislative change aims to increase accessibility to ivermectin for individuals requiring treatment for parasitic conditions
• In August 2025, the U.S. Department of Health and Human Services issued a declaration allowing the FDA to issue Emergency Use Authorizations (EUAs) for animal drugs to treat or prevent infestations caused by the New World Screwworm. This measure aims to protect the U.S. food supply from this parasitic threat
• In August 2025, the United States reported its first human infection with the New World screwworm (Cochliomyia hominivorax) in over six decades. The case involved a Maryland resident who had recently traveled from El Salvador, a region experiencing a screwworm outbreak. The infection was identified through telediagnosis by the CDC
• In March 2025, a rare case of urogenital myiasis was reported in a 76-year-old man in Nepal. The patient, who had an enlarged prostate and used a catheter, developed an infestation of maggots in his urethra and bladder. Treatment involved the use of turpentine oil to remove the maggots, bladder irrigation with saline, administration of ivermectin, and subsequent circumcision to prevent future infections

SKU-60939